Literature DB >> 2433930

Use of calcium antagonists for cardiac arrhythmias.

B N Singh, K Nademanee.   

Abstract

Calcium antagonists have emerged as a new class of antiarrhythmic agents for the control of certain supraventricular and ventricular arrhythmias. Electrophysiologically, these agents are heterogeneous but their main action is mediated through a depressant effect on the slow calcium channel in cardiac muscle, most readily demonstrated in isolated tissue preparations. In vivo, their actions are modulated by their reflex actions and by their interaction with the autonomic nervous system due to the noncompetitive adrenergic-blocking actions that some of the compounds exhibit. The major agents exerting antiarrhythmic actions are verapamil, diltiazem, gallopamil, tiapamil and bepridil; the dihydropyridines are devoid of electrophysiologic actions in vivo. Calcium antagonists prolong intranodal conduction time, lengthen the effective and functional refractory periods in the atrioventricular node but exert little or no effect on atrial, ventricular, His-Purkinje or bypass tract conduction or refractoriness (except in the case of bepridil, which has additional electrophysiologic properties). These effects form the basis of the clinical antiarrhythmic effects of this class of agents. The most striking action is the predictable and prompt termination of the reentrant supraventricular tachycardia by intravenous verapamil and diltiazem and the slowing of the ventricular response in atrial flutter and fibrillation. These agents may also be of value in the long-term control of ventricular response in atrial flutter and fibrillation; their role in multifocal atrial tachycardia and other ectopic tachycardias is less well defined. Calcium antagonists reverse ischemic ventricular arrhythmias caused by coronary artery spasm but exert little or no action in the usual forms of sustained ventricular tachyarrhythmias associated with severe structural heart disease. They are poor suppressants of ventricular premature complexes. Recent data have established their role in exercise-induced tachycardia occurring in the context of ischemic heart disease; they are also of value in ventricular tachycardia occurring in young patients who develop tachycardia with a right bundle branch block and left axis deviation morphology, an arrhythmia thought to be due to triggered automaticity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433930     DOI: 10.1016/0002-9149(87)90096-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Calcium-channel blockers and anaesthesia.

Authors:  P G Durand; J J Lehot; P Foëx
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

Review 2.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 3.  Protective effects of calcium antagonists against ischaemia and reperfusion damage.

Authors:  R Ferrari; O Visioli
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs.

Authors:  John Larson; Lucas Rich; Amrish Deshmukh; Erin C Judge; Jackson J Liang
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

5.  Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.

Authors:  N T Fuenmayor; B M Faggin; L X Cubeddu
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

Review 7.  Management of trigeminal autonomic cephalgias and hemicrania continua.

Authors:  Manjit S Matharu; Christopher J Boes; Peter J Goadsby
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Effects of L-type Calcium Channel Antagonists Verapamil and Diltiazem on fKv1.4ΔN Currents in Xenopus oocytes.

Authors:  Hui Chen; Dong Zhang; Jiang Hua Ren; Sheng Ping Chao
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.